DLL3 and neuroendocrine carcinoma: The comparison between GEP-NET G3 and GEP-NEC revealed no significant differences when all intensities of DLL3 expression were considered (8/15 DLL3-positive GEP-NET G3 vs. 58/133 DLL3-positive GEP-NEC; p = 0.508).